eGenesis Announced New Funding To Address Organ Shortage

Want to share this story?

eGenesis, a Cambridge, Mass. biotech firm utilizing breakthrough gene editing technologies for development of safe and effective human-compatible organs to address the worldwide shortage of organs, announced it has completed its latest funding round.

The $100 million Series B round was led by Fresenius Medical Care Ventures, with participation of new investors Wellington Partners and Leaps by Bayer, along with incumbent investors Biomatics Capital, Alta Partners, ARCH Venture Partners and Khosla Ventures.

“With this new round of financing from industry leaders, eGenesis is well positioned to continue to advance the development of human-compatible organs to address the dire shortage in the U.S. and around the world,” said Paul Sekhri, president and CEO of eGenesis, in a statement. “The concept of cross-species organ replacement, known as xenotransplantation, has re-emerged due to recent advancements in gene editing led by eGenesis, and will become a safe and effective solution for the hundreds of thousands of patients currently on the organ transplant wait list globally.”

“The eGenesis approach represents a truly transformational option for patients with kidney disease,” adds Dr. Olaf Schermeier, CEO for global research and development of Fresenius Medical Care. “We look forward to providing our industry leading experience in treating patients with kidney disease to support the company as they aim to bring their solution into the clinical setting.”

Al Wiegman, FMVC’s Head of Ventures, Jurgen Eckhardt and Dr. Lucio Lannone, Director of Venture of Investments at Leaps by Bayer, all will join eGenesis Board of Directors as part of the funding arrangement.